CKD-498
/ Chong Kun Dang
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 28, 2024
A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia
(clinicaltrials.gov)
- P2 | N=121 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Recruiting ➔ Completed | Trial completion date: Apr 2024 ➔ Dec 2023 | Trial primary completion date: Apr 2024 ➔ Dec 2023
Trial completion • Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology
January 23, 2023
A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia
(clinicaltrials.gov)
- P2 | N=120 | Recruiting | Sponsor: Chong Kun Dang Pharmaceutical | Initiation date: Dec 2002 ➔ Dec 2022
Trial initiation date • Alopecia
January 10, 2023
A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia
(clinicaltrials.gov)
- P2 | N=120 | Recruiting | Sponsor: Chong Kun Dang Pharmaceutical
New P2 trial • Alopecia
1 to 3
Of
3
Go to page
1